» Articles » PMID: 19594295

Overexpression of Secreted Frizzled-related Protein 1 Inhibits Bone Formation and Attenuates Parathyroid Hormone Bone Anabolic Effects

Overview
Date 2009 Jul 15
PMID 19594295
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Secreted frizzled-related protein 1 (sFRP1) is an antagonist of Wnt signaling, an important pathway in maintaining bone homeostasis. In this study we evaluated the skeletal phenotype of mice overexpressing sFRP1 (sFRP1 Tg) and the interaction of parathyroid hormone (PTH) treatment and sFRP1 (over)expression. Bone mass and microarchitecture were measured by micro-computed tomography (microCT). Osteoblastic and osteoclastic cell maturation and function were assessed in primary bone marrow cell cultures. Bone turnover was assessed by biochemical markers and dynamic bone histomorphometry. Real-time PCR was used to monitor the expression of several genes that regulate osteoblast maturation and function in whole bone. We found that trabecular bone mass measurements in distal femurs and lumbar vertebral bodies were 22% and 51% lower in female and 9% and 33% lower in male sFRP1 Tg mice, respectively, compared with wild-type (WT) controls at 3 months of age. Genes associated with osteoblast maturation and function, serum bone formation markers, and surface based bone formation were significantly decreased in sFRP1 Tg mice of both sexes. Bone resorption was similar between sFRP1 Tg and WT females and was higher in sFRP1 Tg male mice. Treatment with hPTH(1-34) (40 microg/kg/d) for 2 weeks increased trabecular bone volume in WT mice (females: +30% to 50%; males: +35% to 150%) compared with sFRP1 Tg mice (females: +5%; males: +18% to 54%). Percentage increases in bone formation also were lower in PTH-treated sFRP1 Tg mice compared with PTH-treated WT mice. In conclusion, overexpression of sFRP1 inhibited bone formation as well as attenuated PTH anabolic action on bone. The gender differences in the bone phenotype of the sFRP1 Tg animal warrants further investigation.

Citing Articles

Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease.

Hu L, Chen W, Qian A, Li Y Bone Res. 2024; 12(1):39.

PMID: 38987555 PMC: 11237130. DOI: 10.1038/s41413-024-00342-8.


Research Progress on the Mechanism of the SFRP-Mediated Wnt Signalling Pathway Involved in Bone Metabolism in Osteoporosis.

An F, Song J, Chang W, Zhang J, Gao P, Wang Y Mol Biotechnol. 2024; 66(5):975-990.

PMID: 38194214 DOI: 10.1007/s12033-023-01018-0.


Therapeutic approaches to activate the canonical Wnt pathway for bone regeneration.

Nelson A, Fontana G, Miclau E, Rongstad M, Murphy W, Huard J J Tissue Eng Regen Med. 2022; 16(11):961-976.

PMID: 36112528 PMC: 9826348. DOI: 10.1002/term.3349.


Inflammation and Bone Metabolism in Rheumatoid Arthritis: Molecular Mechanisms of Joint Destruction and Pharmacological Treatments.

Maeda K, Yoshida K, Nishizawa T, Otani K, Yamashita Y, Okabe H Int J Mol Sci. 2022; 23(5).

PMID: 35270012 PMC: 8911191. DOI: 10.3390/ijms23052871.


Wnt Pathway Extracellular Components and Their Essential Roles in Bone Homeostasis.

Martinez-Gil N, Ugartondo N, Grinberg D, Balcells S Genes (Basel). 2022; 13(1).

PMID: 35052478 PMC: 8775112. DOI: 10.3390/genes13010138.


References
1.
Yao W, Cheng Z, Busse C, Pham A, Nakamura M, Lane N . Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008; 58(6):1674-86. PMC: 3892702. DOI: 10.1002/art.23454. View

2.
Huang J, Sakata T, Pfleger L, Bencsik M, Halloran B, Bikle D . PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res. 2004; 19(2):235-44. DOI: 10.1359/JBMR.0301226. View

3.
Goldring S, Goldring M . Eating bone or adding it: the Wnt pathway decides. Nat Med. 2007; 13(2):133-4. DOI: 10.1038/nm0207-133. View

4.
Bodine P, Stauffer B, Ponce-de-Leon H, Bhat R, Mangine A, Seestaller-Wehr L . A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone. 2009; 44(6):1063-8. DOI: 10.1016/j.bone.2009.02.013. View

5.
van Meurs J, Trikalinos T, Ralston S, Balcells S, Brandi M, Brixen K . Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA. 2008; 299(11):1277-90. PMC: 3282142. DOI: 10.1001/jama.299.11.1277. View